TransCelerate BioPharma Accelerates Digital Transformation in Clinical R&D
Event summary
- TransCelerate BioPharma released its 2025 Annual Report on February 19, 2026, highlighting progress in digital data flow, regulatory guideline adoption, and clinical data sharing.
- By September 2025, a majority of TransCelerate's member companies reported progress in implementing Digital Data Flow (DDF) initiatives.
- Use of the DataCelerate platform more than doubled from the previous year, with continued growth in peer-reviewed publications from shared datasets.
- TransCelerate engaged with seven health authorities across three continents on modernizing individual case safety reporting.
The big picture
TransCelerate BioPharma's 2025 Annual Report underscores the growing importance of cross-industry collaboration in addressing the complexities of clinical R&D. With member companies investing over $130 billion annually in R&D, the organization's initiatives aim to streamline trial operations and accelerate the delivery of new therapies. The report highlights a strategic shift towards digitization and regulatory alignment, reflecting broader industry trends towards more efficient and patient-focused clinical research.
What we're watching
- Digital Protocol Adoption
- How the pace of digital protocol adoption for regulatory use will impact trial execution and data exchange efficiency.
- Regulatory Collaboration
- Whether TransCelerate can sustain momentum in strengthening dialogue with global health authorities on modernizing safety monitoring.
- Pragmatic Trial Integration
- The extent to which embedded pragmatic trials will become a standard practice in clinical research.
Related topics